Kantaro Biosciences Gets FDA Emergency Use Authorization for Coronavirus Antibody Test

Nov 25, 2020

|

NEW YORK — Kantaro Biosciences said on Wednesday that its COVID-SeroKlir SARS-CoV-2 antibody test has received Emergency Use Authorization from the US Food and Drug Administration.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Kantaro Biosciences Gets FDA Emergency Use Authorization for Coronavirus Antibody Test

To read the full story....

Breaking News

Genetic Technologies to Raise $6.6M in Direct Offering

Numares Collaborating With Bruker on NMR-based Diagnostics

CareDx Prices $175M Common Stock Offering

Oncocyte to Raise $25M in Stock Sale to Institutional Investors

Invitae to Raise $400M in Proposed Public Offering

Natera Sues Inivata, Alleging Infringement of Cancer Testing Patents

Featured White Papers

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

What's Popular?

Bio-Rad, United Biomedical Get FDA Emergency Use Authorizations for Coronavirus Tests

Ortho Clinical Diagnostics Launches IPO at $20 to $23 Per Share

Jonathan Rothberg-Led Startup Looks to Bring Disposable POC SARS-CoV-2 Test to Market

SureScreen Dx Antigen Test Moves to Forefront of UK Effort to Control Spread of COVID-19

Finnish Diagnostic Firm Actim Gets CE Mark for SARS-CoV-2 Antibody Test

Sponsorships